Just to go ahead and give everyone a quick refresher, CAR-T treatment aims to reengineer a patient’s T-cells so that they will eliminate harmful B-cells that cause all sorts of problems. To this day, ...
Cartesian Therapeutics, Inc. has announced the enrollment of the first participant in its Phase 3 AURORA trial for Descartes-08, its lead cell therapy candidate aimed at treating myasthenia gravis (MG ...
A look at the shareholders of Cartesian Growth Corporation (NASDAQ:GLBL) can tell us which group is most powerful. Insiders often own a large chunk of younger, smaller, companies while huge companies ...
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Cartesian Therapeutics (NASDAQ:RNAC) stock is falling on Monday after the clinical-stage biopharmaceutical company revealed a delisting notice. This notice comes from the Nasdaq Listing Qualifications ...
BOSTON and NEW YORK, May 11, 2026 (GLOBE NEWSWIRE) -- Factorial Inc. (“Factorial” or the “Company”), a leader in solid-state battery technology, and Cartesian Growth Corporation III (“Cartesian III”) ...
NEW YORK--(BUSINESS WIRE)--Cartesian Growth Corporation (“Cartesian”) (NASDAQ: GLBL), a publicly traded special purpose acquisition company, announced today that in an extraordinary general meeting on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results